Adriano Alatri and Lucia Mazzolai* Pages 1 - 12 ( 12 )
Bleeding represents the most important complication of antithrombotic treatment, including anticoagulant and antiplatelet therapies. A number of scores were proposed to evaluate the risk of bleeding both for anticoagulant and antiplatelet treatment. In the last decade, 5 bleeding risk scores were published for use in atrial fibrillation patients, and 3 scores for patients receiving anticoagulants for venous thromboembolism therapy or prophylaxis. In addition, 3 scores were recently developed to assess inhospital or short-term bleeding risk in patients receiving antiplatelet therapy after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). Furthermore, 3 additional scores have focused on long-term bleeding in outpatients receiving dual antiplatelet therapy after PCI. The aim of this review is to consider the evidence on bleeding scores.
Bleeding, clinical predictive rules, atrial fibrillation, venous thromboembolism, acute coronary syndrome, percutaneous coronary intervention, anticoagulants, antiplatelet therapy.
Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Lausanne, Division of Angiology, Heart and Vessel Department, Lausanne University Hospital, Lausanne